Pasar al contenido principal

CONTROL INMUNOMETABOLICO DE LA FAGOCITOSIS MICROGLIAL

RTI2018-099267-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION ACHUCARRO BASQUE CENTER FOR NEUROSCIENCE FUNDAZIOA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Microglial phagocytosis dysfunction in stroke is driven by energy depletion and induction of autophagy

  • Beccari, Sol
  • Sierra-Torre, Virginia
  • Valero, Jorge
  • Pereira-Iglesias, Marta
  • García-Zaballa, Mikel
  • Soria, Federico N.
  • De Las Heras-Garcia, Laura
  • Carretero-Guillén, Alejandro
  • Capetillo-Zarate, Estibaliz
  • Domercq, María
  • Huguet, Paloma R.
  • Ramonet, David
  • Osman, Ahmed M.
  • Han, Wei
  • Domínguez, Cecilia
  • Faust, Travis E.
  • Touzani, Omar
  • Pampliega, Olatz
  • Boya, Patricia
  • Schafer, Dorothy
  • Mariño, Guillermo
  • Canet-Soulas, Emmanuelle
  • Blomgren, Klas
  • Plaza-Zabala, Ainhoa
  • Sierra, Amanda
31 p.-12 fig.-1 tab. We dedicate this paper to Takashi Umekawa, who generated the HI model at the Karolinska Institute, and unfortunately passed away in 2018., Microglial phagocytosis of apoptotic debris prevents buildup damage of neighbor neurons and inflammatory responses. Whereas microglia are very competent phagocytes under physiological conditions, we report their dysfunction in mouse and preclinical monkey models of stroke (macaques and marmosets) by transient occlusion of the medial cerebral artery (tMCAo). By analyzing recently published bulk and single cell RNA sequencing databases, we show that the phagocytosis dysfunction was not explained by transcriptional changes. In contrast, we demonstrate that the impairment of both engulfment and degradation was related to energy depletion triggered by oxygen and nutrient deprivation (OND), which led to reduced process motility, lysosomal exhaustion, and the induction of a protective macroautophagy/autophagy response in microglia. Basal autophagy, in charge of removing and recycling intracellular elements, was critical to maintain microglial physiology, including survival and phagocytosis, as we determined both in vivo and in vitro using pharmacological and transgenic approaches. Notably, the autophagy inducer rapamycin partially prevented the phagocytosis impairment induced by tMCAo in vivo but not by OND in vitro, where it even had a detrimental effect on microglia, suggesting that modulating microglial autophagy to optimal levels may be a hard to achieve goal. Nonetheless, our results show that pharmacological interventions, acting directly on microglia or indirectly on the brain environment, have the potential to recover phagocytosis efficiency in the diseased brain. We propose that phagocytosis is a therapeutic target yet to be explored in stroke and other brain disorders and provide evidence that it can be modulated in vivo using rapamycin. Abbreviations: AIF1/IBA1: allograft inflammatory factor 1; AMBRA1: autophagy/beclin 1 regulator 1; ATG4B: autophagy related 4B, cysteine peptidase; ATP: adenosine triphosphate; BECN1: beclin 1, autophagy related; CASP3: caspase 3; CBF: cerebral blood flow; CCA: common carotid artery; CCR2: chemokine (C-C motif) receptor 2; CIR: cranial irradiation; Csf1r/v-fms: colony stimulating factor 1 receptor; CX3CR1: chemokine (C-X3-C motif) receptor 1; DAPI: 4’,6-diamidino-2-phenylindole; DG: dentate gyrus; GO: Gene Ontology; HBSS: Hanks’ balanced salt solution; HI: hypoxia-ischemia; LAMP1: lysosomal-associated membrane protein 1; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MCA: medial cerebral artery; MTOR: mechanistic target of rapamycin kinase; OND: oxygen and nutrient deprivation; Ph/A coupling: phagocytosis-apoptosis coupling; Ph capacity: phagocytic capacity; Ph index: phagocytic index; SQSTM1: sequestosome 1; RNA-Seq: RNA sequencing; TEM: transmission electron microscopy; tMCAo: transient medial cerebral artery occlusion; ULK1: unc-51 like kinase 1. © 2023 The Author(s)., This work was supported by grants from the Spanish Ministry of Science and Innovation Competitiveness MCIN/AEI/10.13039/501100011033 (https://www.ciencia.gob.es/) and ERDF “A way to make Europe” (RTI2018-099267-B-I00 and RYC-2013-12817 to AS; RTI2018–097948-A-100 and RYC-2016–20480 to OP), a Tatiana Foundation Award (P-048-FTPGB 2018) to AS a Basque Government Department of Education project (PIBA 2020_1_0030; http://www.euskadi.eus/basque-government/department-education/) to AS, a Basque Government Department of Economic development, Sustainability and environment (ELKARTEK KK-2020/00034; https://www.spri.eus/en/) to ECZ, and . SB is recipient of predoctoral fellowship from the Spanish Ministry of Economy and Competitiveness, and VST is recipient of predoctoral fellowship from the Basque Government., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders

  • Alvaro-Espinosa, Laura
  • Marquez-Galera, Angel
  • Priego, Neibla
  • García-Calvo, Virginia
  • Perea-García, Maria
  • Hernandez-Oliver, Carolina
  • Retana, Diana
  • Sanchez, Oliva
  • Pablos-Aragoneses, Ana de
  • García-Gómez, Pedro
  • Graña-Castro, Osvaldo
  • Lapuente-Santana, Óscar
  • Serrano-Ron, Laura
  • Al-Shahrour, Fatima
  • Cayuela López, Ana
  • Peset, Isabel
  • Megías, Diego
  • Ola, Mihaela
  • Varešlija, Damir
  • Young, Leonie S.
  • Martí-Mateos, Yolanda
  • Enríquez, Jose A.
  • Hernández-Encinas, Elena
  • Blanco-Aparicio, Carmen
  • Soengas, María S.
  • Bernhagen, Juergen
  • Antón-Fernández, Alejandro
  • Ávila, Jesús
  • Marchena, Miguel A.
  • Torres, Maximiliano
  • Castro Soubriet, Fernando de
  • Márquez-Ropero, Mar
  • Sierra, Amanda
  • López-Atalaya, José P.
  • Valiente, Manuel
  • RENACER Group
The upregulation of CD74, a chaperone involved in MHC-II antigen processing, has been mostly interpreted as indicative of antigen presentation in multiple brain disorders. However, CD74 expression has also been described in cancer cells across multiple tumor types and in the tumor microenvironment, notably in glioma. In this study, we found that the presence of CD74+ microglia/macrophages, which was induced by increased levels of interferon γ in brains affected by metastases, did not relate to its canonical pathway. Instead, the alternative function of CD74 as a cytokine receptor was pivotal. Proliferating cancer cells produced high levels of the ligand migration inhibitory factor (MIF) that bound the CD74 receptor and induced its translocation to the nucleus where it activated an NF-κB-dependent program that promoted metastatic progression. In patients, a CD74 signature was associated with more aggressive progression of brain metastatic disease, although it had no clinical correlation with the matched primary tumor. Interestingly, a pan-disease noncanonical and clinically relevant signature derived from the CD74+ myeloid population was identified that occurred in additional brain disorders, including Alzheimer's disease and multiple sclerosis. The brain-penetrant drug ibudilast, which prevents the binding of MIF to CD74, decreased brain metastasis in experimental models in vivo and in patient-derived organotypic cultures ex vivo in a primary tumor-agnostic manner. These findings suggest that MIF/CD74-induced reprogramming of myeloid cells in brain disorders is a vulnerability that could be exploited therapeutically against brain metastases and possibly other brain disorders., We thank all members of the Brain Metastasis Group for critical discussion of the manuscript; the CNIO Core Facilities for their excellent assistance; and Estefanía Sánchez-Jiménez (F. de Castro laboratory at Instituto Cajal-CSIC) and the staff at the Animal Facilities of the Instituto Cajal-CSIC for their extraordinary help with animals of the cuprizone demyelinating murine model of multiple sclerosis. Special thanks to patients and their families who donated valuable materials to RENACER and all site personnel, investigators, funders, and industry partners who supported the generation of the data within this study. Postmortem cortical brain tissue blocks from patients with multiple sclerosis and controls, as well as the associated clinical and neuropathologic data, were supplied by the Multiple Sclerosis & Parkinson’s Tissue Bank at Imperial College (London, United Kingdom), funded by the Multiple Sclerosis Society of Great Britain and Northern Ireland, registered charity 207495. We thank J. Massagué (MSKCC) for some of the BrM cell lines. This study was funded by La Marató (201906-30-31-32; M. Valiente), MICIU (SAF2017-89643-R, SAF2014-57243-R, and SAF2015-62547-ERC to M. Valiente; PID2022-143110OB-I00 and RED2024-153909-E to F. de Castro), H2020-FETOPEN (828972; M. Valiente), Bristol Myers Squibb MRA Young Investigator Award (498103; M. Valiente), Cancer Research Institute (Clinic and Laboratory Integration Program CRI Award 2018; 54545; M. Valiente), LAB AECC 2019 (LABAE19002VALI; M. Valiente), AECC Coordinados (PRYCO234528VALI; M. Valiente), ERC CoG (864759; M. Valiente), and ERANET-TRANSCAN-3 (TRANSCAN2021-203; M. Valiente) with funds from Instituto de Salud Carlos III/NextGenerationEU/PRTR (AC20/00114) and FC AECC (TRNSC213878VALI), CaixaResearch Health (HR23-00051; M. Valiente), MINECO-Ramón y Cajal (RYC-2013-13365; M. Valiente), MICIU/AEI/10.13039/501100011033 and ERDF (RTI2018-102260-B-I00; J.P. Lopez-Atalaya), Generalitat Valenciana (PROMETEO/2020/007; J.P. Lopez-Atalaya), Ramón Areces Foundation (CIVP20S10662 to E. Ortega-Paino/M.-J. Artiga; CIVP19S8163 to M. Valiente; and CIVP19A5917 to F. de Castro), Spanish Ministry of Science and Innovation Competitiveness MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” (RTI2018-099267-B-I00 and PID2022-136698OB-I00; A. Sierra), Basque Government grants (IT1473-22; A. Sierra), Alzheimer Association award (AARG-NTF-24-1304352; A. Sierra), Breast Cancer Ireland (18239A01; L.S. Young), Research Ireland (19/FFP/6443; L.S. Young, 20/FFP-P/8597; D. Varešlija, and 23/SPP/11783; L.S. Young, D. Varešlija), Breast Cancer Now (2021 July PCC1460; L.S. Young, D. Varešlija, 2019 Aug SF1310 with the generous support of Walk the Walk; D. Varešlija), MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/Plan de Recuperación Transformación y Resiliencia, PRTR (RTI2018-099357-B-I00, PID2021-1279880B, and TED2021-131611B-I00; J.A. Enríquez), CIBERFES (CB16/10/00282; J.A. Enríquez), Foundation Leducq (17CVD04; J.A. Enríquez), MCIN/AEI/10 PID2023-147213OB-I00 (M.S. Soengas), ERC-Advanced Grant 884699 (M.S. Soengas), La Caixa International PhD Program Fellowship-Marie Sklodowska-Curie (LCF/BQ/DI17/11620028; P. García-Gómez and LCF/BQ/DI19/11730044; A. de Pablos-Aragoneses), AECC postdoctoral fellowship (POSTD19016PRIE; N. Priego), MINECO-Severo Ochoa PhD Fellowship (BES-2017-081995; L. Alvaro-Espinosa), FPI-Severo Ochoa Fellowship PRE2018-083478 awarded by MICIU/AEI/10.13039/501100011033, and European Social Funds (FSE invierte en tu futuro; Y. Martí-Mateos). M. Valiente is an EMBO YIP member (4053). The CNIC is supported by the Instituto de Salud Carlos III, the Ministerio de Ciencia, Innovación y Universidades, and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIU/AEI/10.13039/501100011033). The Instituto de Neurociencias is a “Centre of Excellence Severo Ochoa” (CEX2021-001165-S funded by MCIU/AEI/10.13039/501100011033). CNIO is supported by the ISCIII, the Ministerio de Ciencia e Innovación, and is a Severo Ochoa Center of Excellence (SEV-2015-0510)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2020-001041-S), With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed